Marmarelis, Melina ElpiDavis, Meredith R.Sethi, NilayKrajewksi, Katherine M.McKay, Rana R.Choueiri, ToniOtt, Patrick2016-05-022016Marmarelis, Melina E., Meredith R. Davis, Nilay S. Sethi, Katherine M. Krajewksi, Rana R. McKay, Toni K. Choueiri, and Patrick A. Ott. 2016. “Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma.” Journal for Immunotherapy of Cancer 4 (1): 26. doi:10.1186/s40425-016-0129-x. http://dx.doi.org/10.1186/s40425-016-0129-x.2051-1426http://nrs.harvard.edu/urn-3:HUL.InstRepos:26860040Blockade of the immunological checkpoint programmed death 1 (PD-1) using monoclonal antibodies has shown robust anti-tumor activity across a broad range of solid and hematological malignancies including melanoma and renal cell carcinoma (RCC). Characteristic markers such as the presence of tumor infiltrating lymphocytes, PD-L1 status, and mutational load may be equally or even more important in predicting clinical benefit from PD-1 pathway blockade than tumor histology. This case of a patient with concurrent metastatic melanoma and metastatic RCC, both of which were controlled for more than a year after a single dose of the anti-PD-1 antibody pembrolizumab, illustrates the potential to simultaneously treat distinct immunogenic tumors with anti-PD-1 agents.en-USPD-1Immune checkpoint blockadeAntibody therapyMelanomaRenal cell cancerImmunotherapyConcurrent cancerJournal Article2016-05-0210.1186/s40425-016-0129-x